Arrowhead Pharmaceuticals Inc Cash Flow Conversion Efficiency
Arrowhead Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.49 Million) by net assets ($503.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arrowhead Pharmaceuticals Inc (1997–2025)
Cash flow conversion efficiency of Arrowhead Pharmaceuticals Inc from 1997 to 2025. This chart illustrates how Arrowhead Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Arrowhead Pharmaceuticals Inc for real-time trading data and today's change.
Arrowhead Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Arrowhead Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arrowhead Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see ARWR company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Element Solutions Inc
NYSE:ESI
|
0.033x |
|
Bid Corporation Ltd
JSE:BID
|
0.182x |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
0.043x |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
-0.159x |
|
Redeia Corporacion S.A.
MC:RED
|
0.064x |
|
Pentair PLC
NYSE:PNR
|
0.153x |
|
Companhia Paranaense de Energia - COPEL
SA:CPLE3
|
0.023x |
|
American Airlines Group
NASDAQ:AAL
|
-0.119x |
Annual Cash Flow Conversion Efficiency for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Arrowhead Pharmaceuticals Inc from 1997 to 2025. Review how much free cash does Arrowhead Pharmaceuticals Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $503.42 Million | $179.55 Million | 0.357x | +114.72% |
| 2024-09-30 | $191.06 Million | $-462.85 Million | -2.423x | -352.04% |
| 2023-09-30 | $287.16 Million | $-153.89 Million | -0.536x | -64.69% |
| 2022-09-30 | $418.34 Million | $-136.13 Million | -0.325x | -177.70% |
| 2021-09-30 | $408.82 Million | $171.22 Million | 0.419x | +302.75% |
| 2020-09-30 | $461.78 Million | $-95.39 Million | -0.207x | -129.13% |
| 2019-09-30 | $244.04 Million | $173.03 Million | 0.709x | +243.00% |
| 2018-09-30 | $95.24 Million | $-47.22 Million | -0.496x | -67.49% |
| 2017-09-30 | $80.87 Million | $-23.94 Million | -0.296x | +56.34% |
| 2016-09-30 | $95.02 Million | $-64.43 Million | -0.678x | -13.11% |
| 2015-09-30 | $109.62 Million | $-65.71 Million | -0.599x | -180.92% |
| 2014-09-30 | $165.99 Million | $-35.42 Million | -0.213x | +71.15% |
| 2013-09-30 | $25.73 Million | $-19.03 Million | -0.740x | +57.53% |
| 2012-09-30 | $8.81 Million | $-15.34 Million | -1.741x | -305.88% |
| 2011-09-30 | $12.56 Million | $-5.39 Million | -0.429x | +54.98% |
| 2010-09-30 | $8.08 Million | $-7.70 Million | -0.953x | +69.69% |
| 2009-09-30 | $4.86 Million | $-15.28 Million | -3.145x | -40.26% |
| 2008-09-30 | $12.30 Million | $-27.58 Million | -2.242x | -148.54% |
| 2007-09-30 | $26.46 Million | $-23.87 Million | -0.902x | -92.76% |
| 2006-09-30 | $31.61 Million | $-14.79 Million | -0.468x | -44.09% |
| 2005-09-30 | $28.02 Million | $-9.10 Million | -0.325x | -57.54% |
| 2004-09-30 | $11.23 Million | $-2.31 Million | -0.206x | -85.73% |
| 2003-09-30 | $1.42 Million | $-157.60K | -0.111x | -262.64% |
| 2002-09-30 | $-1.55 Million | $-105.83K | 0.068x | +8.82% |
| 2001-09-30 | $-1.30 Million | $-81.81K | 0.063x | -11.57% |
| 2000-09-30 | $-1.13 Million | $-80.09K | 0.071x | +100.61% |
| 1999-09-30 | $-996.10K | $-35.22K | 0.035x | +101.32% |
| 1998-09-30 | $-2.63 Million | $-46.15K | 0.018x | +1091.72% |
| 1997-09-30 | $-2.58 Million | $4.56K | -0.002x | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more